Reaction

Fanconi Syndrome reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,387 reports · 49 co-occurring drugs

As of the last recalculation, Fanconi Syndrome appears in 1,387 FAERS reports alongside 49 co-occurring drug terms. The strongest observed disproportionality signal is TENOFOVIR DISOPROXIL FUMARATE TABLETS (PRR 175.2).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Tenofovir Disoproxil Fumarate Tablets94175.2177.1
Tenofovir Disoproxil Fumarate18194.494.9
Ifosfamide11789.289.6
Lamivudine Oral13588.689.1
Lamivudine14377.377.7
Mesna4175.375.6
Mesna Injection4074.875.1
Lopinavir And Ritonavir5664.664.8
Entecavir4458.458.6
Atazanavir5357.557.7
Ritonavir9149.950.1
Efavirenz3649.749.9
Ritonavir 100 Mg4748.849.0
Valproic Acid8744.144.3
Abacavir Sulfate2844.044.1
Clobazam5535.235.2
Zonisamide3233.233.3
Valproate Sodium4433.033.0
Nevirapine1830.330.4
Zoledronic Acid7529.629.6
Darunavir2828.328.4
Phenobarbital2627.427.5
Emtricitabine And Tenofovir Disoproxil Fumarate6923.823.9
Zidovudine2022.822.8
Deferasirox3620.920.9
Bupivacaine1219.419.5
Norepinephrine1217.017.0
Dronabinol916.916.9
Cefuroxime1215.915.9
Etoposide7215.415.5
Rocuronium Bromide1215.415.4
Midazolam2313.913.9
Doxorubicin7713.713.7
Midazolam Hydrochloride2313.013.0
Norepinephrine Bitartrate1212.612.6
Gemfibrozil1212.012.0
Raltegravir1311.911.9
Dolutegravir Sodium711.711.7
Topiramate6410.810.8
Busulfan1110.610.6
Cisplatin5310.510.6
Rifampicin710.410.4
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate610.010.0
Carboplatin678.38.3
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide57.57.5
Pitavastatin Calcium57.47.4
Brivaracetam46.76.7
Emtricitabine And Tenofovir Alafenamide56.66.6
Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate43.33.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.